MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11845-020-02336-x

Медицинская библиотека · Irish journal of medical science · 2020

Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre.

Griffin Laoise, Boggs Jennifer, Ramsay Bart, Hackett Caitriona, Ahmad Kashif, Lynch Maeve

СтатьяОбзорПеревод в очереди

Аннотация

Secukinumab is a novel anti-interleukin-17A agent that has achieved a 75% decrease from baseline in Psoriasis Area and Severity Index (PASI 75) in 77-81% of patients treated in clinical trials Langley et al. (N Engl J Med 371:326-338, 2014). There is limited data on the use of secukinumab outside of clinical trials. We provide real-world data on the efficacy and safety of secukinumab in patients with severe psoriasis attending an outpatient dermatology service. In our retrospective review, we demonstrate (PASI 75) a response rate of 47% in patients previously treated with multiple systemic and biologics. Our efficacy is comparable to that seen in the Signature study who examined similar populations. Response was maintained at follow-up of almost 1 year with acceptable safety data. Patients with psoriatic arthritis were more likely to remain on secukinumab than those without at last clinic follow-up.

Для цитирования: Griffin Laoise, Boggs Jennifer, Ramsay Bart, Hackett Caitriona, Ahmad Kashif, Lynch Maeve. Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre.. Irish journal of medical science. 2020. DOI: 10.1007/s11845-020-02336-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.